Hematologic abnormalities are common in patients with leukemia.
血液学异常在白血病患者中很常见。
The complete blood count (CBC) is a
hematologic test that measures red and white blood cells, as well as platelets.
全血细胞计数（CBC）是一项血液学检查，用于测量红细胞、白细胞和血小板的数量。
Her anemia was diagnosed based on her
hematologic profile.
她的贫血是根据她的血液学特征诊断的。
He underwent a bone marrow biopsy for
hematologic evaluation.
他接受了骨髓活检以进行血液学评估。
The patient's leukocyte count indicated a severe
hematologic disorder.
患者的白细胞计数表明有严重的血液系统疾病。
Hematologic disorders can manifest themselves through fatigue and frequent infections.
血液系统疾病可能会表现为疲劳和频繁感染。
She received chemotherapy to treat her
hematologic malignancy.
她接受了化疗来治疗她的血液系统恶性肿瘤。
Hematologic parameters, such as RBCs and Hb levels, were closely monitored during the treatment.
在治疗期间，对红细胞和血红蛋白等血液学参数进行了密切监测。
Hematologic recovery after surgery can take several weeks.
手术后血液学恢复可能需要几周时间。
Hematologic tests are essential for diagnosing and monitoring blood-related diseases.
血液学检查对于诊断和监控与血液有关的疾病至关重要。
Experts said that hematopoietic stem cell transplantation is often the main means for patients with hematologic malignancies, but about 30 to 70 percent of patients who undergo allogeneic hematopoietic stem cell transplantation will develop cGVHD.
专家表示，造血干细胞移植通常是血液系统恶性肿瘤患者的主要手段，但接受异基因造血干细胞植入的患者中，约有30%至70%会发生cGVHD。
Experts said that hematologic tumor patients are often at risk of relapse or even multiple relapses.
专家表示，血液肿瘤患者往往有复发甚至多次复发的风险。
Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed globally for the treatment of a broad array of both solid tumor and hematologic cancers.
替雷利珠单抗是百济神州免疫肿瘤生物制品项目中的首款药物，正在全球范围内针对多种实体瘤和血液癌症进行开发。
As a third-time participant of the CIIE, Roche is showcasing a wide array of innovative products and therapies covering major diseases such as cancer immunotherapy, hematologic tumors, influenza and rare diseases.
作为第三届中国国际进口博览会的参展商，罗氏带来了涵盖重大疾病领域的众多创新产品和疗法，包括癌症免疫疗法、血液肿瘤、流感和罕见病等。
But the development of therapeutic CD47 antibodies has been hampered by hematologic side-effects, such as severe anemia, because of the binding of CD47 on red blood cells.
John V. Oyler, chairman, co-founder and CEO of BeiGene, said in a press release as the company continues to evaluate Brukinsa's potential in other hematologic cancers, it hopes the FDA approval is the first of many for the therapy.
Its R&D laboratory in Shanghai has developed new drugs for various diseases including hepatitis, lung cancer and hematologic malignancies, through cooperation with China's domestic R&D resources.
Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed globally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
未经许可，严禁转发。QQ交流群：688169419